SCHEMBL2395933

SCHEMBL2395933

NC(=O)c1cccnc1C1CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.50
KDM4E B2RXH2 5/20 0.46
ALDH1A1 P00352 5/20 0.46
HPGD P15428 3/20 0.46
HSD17B10 Q99714 2/20 0.46
MAPT P10636 4/20 0.45
RAB9A P51151 4/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
NPC1 O15118 2/20 0.45
AHR P35869 1/20 0.45
HTT P42858 1/20 0.44
DDB1 Q16531 1/20 0.44
CRBN Q96SW2 1/20 0.44
LMNA P02545 1/20 0.42
OPRL1 P41146 1/20 0.42
NAPRT Q6XQN6 1/20 0.42
ADRA1A P35348 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
CYP3A4 P08684 1/20 0.39
ALOX15 P16050 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3427967 0.93 PARP1 (0.47) PARP1KDM4EALDH1A1HPGDHSD17B10
SCHEMBL3427703 0.93 PARP1 (0.47) PARP1KDM4EALDH1A1HPGDHSD17B10
SCHEMBL4414124 0.92 PARP1 (0.46) PARP1KDM4EALDH1A1HPGDHSD17B10
SCHEMBL29908356 0.92 PARP1 (0.46) PARP1KDM4EALDH1A1HPGDHSD17B10
SCHEMBL5083476 0.89 OPRL1 (0.46) PARP1KDM4EALDH1A1HPGDHSD17B10
SCHEMBL3955549 0.86 PARP1 (0.52) PARP1KDM4EALDH1A1HPGDHSD17B10
SCHEMBL28284464 0.86 PIK3C3 (0.44) PARP1KDM4EALDH1A1HPGDHSD17B10
SCHEMBL29373648 0.85 ALDH1A1 (0.42) PARP1KDM4EALDH1A1HPGDHSD17B10
SCHEMBL29687939 0.85 PARP1 (0.46) PARP1KDM4EALDH1A1HPGDHSD17B10
SCHEMBL1116651 0.85 PARP1 (0.46) PARP1KDM4EALDH1A1HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119654130-A Use of a composition for enhancing night repair related functions of skin 联合利华知识产权控股有限公司 2025-03-18 CN claimed
CN-117915890-A Deodorant composition 联合利华知识产权控股有限公司 2024-04-19 CN claimed
CN-111787903-B Disinfectant composition 联合利华知识产权控股有限公司 2023-08-15 CN claimed
EP-3764975-B1 A SANITIZER COMPOSITION UNILEVER GLOBAL IP LTD (GB) 2021-10-13 EP claimed
CN-111787903-A Disinfectant composition 荷兰联合利华有限公司 2020-10-16 CN claimed
CN-103958478-B Bicyclic dihydroisoquinolin-1-one derivatives 霍夫曼-拉罗奇有限公司 2017-08-01 CN claimed
WO-2006068410-A1 NOVEL 3-(2-AMINO-6-PYRIDINYL)-4-HYDROXYPHENYL AMINE DERIVATIVES LG LIFE SCIENCES, LTD. (KR) 2006-06-29 WO claimed
CN-119654130-A Use of a composition for enhancing night repair related functions of skin 联合利华知识产权控股有限公司 2025-03-18 CN disclosed
CN-117915890-A Deodorant composition 联合利华知识产权控股有限公司 2024-04-19 CN disclosed
CN-111787903-B Disinfectant composition 联合利华知识产权控股有限公司 2023-08-15 CN disclosed
CN-111787903-A Disinfectant composition 荷兰联合利华有限公司 2020-10-16 CN disclosed
CN-103958478-B Bicyclic dihydroisoquinolin-1-one derivatives 霍夫曼-拉罗奇有限公司 2017-08-01 CN disclosed
US-9428456-B2 1-[m-carboxamido(hetero)aryl-methyl]-heterocyclyl-carboxamide derivatives ACTELION PHARMACEUTICALS LTD (CH) 2016-08-30 US disclosed
US-7514456-B2 Nicotinamide derivatives useful as p38 inhibitors SMITHKLINE BEECHAM CORPORATION (US) 2009-04-07 US disclosed
US-20090069320-A1 Substituted 4-Amino-Quinazoline Compounds with Metabotropic Glutamate Receptor Regulating Activity and Uses Thereof GRUENENTHAL GMBH (DE) 2009-03-12 US disclosed
US-20060281763-A1 Carboxamide inhibitors of TGFbeta SCIOS INC. 2006-12-14 US disclosed
US-20060276516-A1 Nicotinamide Derivatives Useful as p38 Inhibitors SMITHKLINE BEECHAM CORPORATION 2006-12-07 US disclosed
US-20060264479-A1 Nicotinamide Derivatives Useful as p38 Inhibitors SMITHKLINE BEECHAM CORPORATION 2006-11-23 US disclosed
US-7125898-B2 Nicotinamide derivatives useful as p38 inhibitors. SMITHKLINE BEECHAM CORPORATION (US) 2006-10-24 US disclosed
US-20050176964-A1 Nicotinamide derivatives useful as p38 inhibitors GLAXOSMITHKLINE LLC 2005-08-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060264479-A1 Nicotinamide Derivatives Useful as p38 Inhibitors MAPK1, MAPK7, MAPK6 PARP1 1139/4885KDM4E 4790/4885ALDH1A1 723/4885
US-20060281763-A1 Carboxamide inhibitors of TGFbeta TGFBR1, TGFBR2, TGFB1 PARP1 873/4885KDM4E 229/4885ALDH1A1 1830/4885
US-20060276516-A1 Nicotinamide Derivatives Useful as p38 Inhibitors MAPK1, MAPK7, MAPK6 PARP1 1139/4885KDM4E 4790/4885ALDH1A1 723/4885
US-20090069320-A1 Substituted 4-Amino-Quinazoline Compounds with Metabotropic Glutamate Receptor Regulating Activity and Uses Thereof GRM1, GRIN1, GRM2 PARP1 4537/4885KDM4E 2026/4885ALDH1A1 2269/4885
US-20050176964-A1 Nicotinamide derivatives useful as p38 inhibitors MAPK1, MAPK7, MAPK6 PARP1 1139/4885KDM4E 4790/4885ALDH1A1 723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.